Safety, Pharmacokinetics, and Mosquito-Lethal Effects of Ivermectin in Combination With Dihydroartemisinin-Piperaquine and Primaquine in Healthy Adult Thai Subjects
© 2019 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics..
Mass administration of antimalarial drugs and ivermectin are being considered as potential accelerators of malaria elimination. The safety, tolerability, pharmacokinetics, and mosquito-lethal effects of combinations of ivermectin, dihydroartemisinin-piperaquine, and primaquine were evaluated. Coadministration of ivermectin and dihydroartemisinin-piperaquine resulted in increased ivermectin concentrations with corresponding increases in mosquito-lethal effect across all subjects. Exposure to piperaquine was also increased when coadministered with ivermectin, but electrocardiograph QT-interval prolongation was not increased. One subject had transiently impaired liver function. Ivermectin mosquito-lethal effect was greater than predicted previously against the major Southeast Asian malaria vectors. Both Anopheles dirus and Anopheles minimus mosquito mortality was increased substantially (20-fold and 35-fold increase, respectively) when feeding on volunteer blood after ivermectin administration compared with in vitro ivermectin-spiked blood. This suggests the presence of ivermectin metabolites that impart mosquito-lethal effects. Further studies of this combined approach to accelerate malaria elimination are warranted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:107 |
|---|---|
| Enthalten in: |
Clinical pharmacology and therapeutics - 107(2020), 5 vom: 01. Mai, Seite 1221-1230 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kobylinski, Kevin C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6A9O50735X |
|---|
| Anmerkungen: |
Date Completed 16.02.2021 Date Revised 15.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cpt.1716 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM303018038 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM303018038 | ||
| 003 | DE-627 | ||
| 005 | 20231225111940.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cpt.1716 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1010.xml |
| 035 | |a (DE-627)NLM303018038 | ||
| 035 | |a (NLM)31697848 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kobylinski, Kevin C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety, Pharmacokinetics, and Mosquito-Lethal Effects of Ivermectin in Combination With Dihydroartemisinin-Piperaquine and Primaquine in Healthy Adult Thai Subjects |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2021 | ||
| 500 | |a Date Revised 15.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics. | ||
| 520 | |a Mass administration of antimalarial drugs and ivermectin are being considered as potential accelerators of malaria elimination. The safety, tolerability, pharmacokinetics, and mosquito-lethal effects of combinations of ivermectin, dihydroartemisinin-piperaquine, and primaquine were evaluated. Coadministration of ivermectin and dihydroartemisinin-piperaquine resulted in increased ivermectin concentrations with corresponding increases in mosquito-lethal effect across all subjects. Exposure to piperaquine was also increased when coadministered with ivermectin, but electrocardiograph QT-interval prolongation was not increased. One subject had transiently impaired liver function. Ivermectin mosquito-lethal effect was greater than predicted previously against the major Southeast Asian malaria vectors. Both Anopheles dirus and Anopheles minimus mosquito mortality was increased substantially (20-fold and 35-fold increase, respectively) when feeding on volunteer blood after ivermectin administration compared with in vitro ivermectin-spiked blood. This suggests the presence of ivermectin metabolites that impart mosquito-lethal effects. Further studies of this combined approach to accelerate malaria elimination are warranted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antimalarials |2 NLM | |
| 650 | 7 | |a Artemisinins |2 NLM | |
| 650 | 7 | |a Insecticides |2 NLM | |
| 650 | 7 | |a Quinolines |2 NLM | |
| 650 | 7 | |a artenimol |2 NLM | |
| 650 | 7 | |a 6A9O50735X |2 NLM | |
| 650 | 7 | |a Ivermectin |2 NLM | |
| 650 | 7 | |a 70288-86-7 |2 NLM | |
| 650 | 7 | |a piperaquine |2 NLM | |
| 650 | 7 | |a A0HV2Q956Y |2 NLM | |
| 650 | 7 | |a Primaquine |2 NLM | |
| 650 | 7 | |a MVR3634GX1 |2 NLM | |
| 700 | 1 | |a Jittamala, Podjanee |e verfasserin |4 aut | |
| 700 | 1 | |a Hanboonkunupakarn, Borimas |e verfasserin |4 aut | |
| 700 | 1 | |a Pukrittayakamee, Sasithon |e verfasserin |4 aut | |
| 700 | 1 | |a Pantuwatana, Kanchana |e verfasserin |4 aut | |
| 700 | 1 | |a Phasomkusolsil, Siriporn |e verfasserin |4 aut | |
| 700 | 1 | |a Davidson, Silas A |e verfasserin |4 aut | |
| 700 | 1 | |a Winterberg, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Hoglund, Richard M |e verfasserin |4 aut | |
| 700 | 1 | |a Mukaka, Mavuto |e verfasserin |4 aut | |
| 700 | 1 | |a van der Pluijm, Rob W |e verfasserin |4 aut | |
| 700 | 1 | |a Dondorp, Arjen |e verfasserin |4 aut | |
| 700 | 1 | |a Day, Nicholas P J |e verfasserin |4 aut | |
| 700 | 1 | |a White, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Tarning, Joel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical pharmacology and therapeutics |d 1960 |g 107(2020), 5 vom: 01. Mai, Seite 1221-1230 |w (DE-627)NLM000015318 |x 1532-6535 |7 nnns |
| 773 | 1 | 8 | |g volume:107 |g year:2020 |g number:5 |g day:01 |g month:05 |g pages:1221-1230 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cpt.1716 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 107 |j 2020 |e 5 |b 01 |c 05 |h 1221-1230 | ||